Vimta Labs (524394) Q4 24/25 earnings summary

Executive summary

• Achieved strong growth in FY2025, with revenue up 19.1% year-over-year to INR 3,482 million, driven by pharmaceutical services and successful regulatory audits.

• Expanded into biologics contract research and development services, targeting revenue generation from Q1 FY2027, with a planned investment of up to INR 500 million.

• Completed major corporate actions, including the amalgamation of EMTAC Laboratories and divestment of the diagnostic business to Thyrocare Technologies.

• Commercialized a new life sciences facility, expanded laboratory space, and completed major regulatory audits.

• Board recommended a final dividend of Rs 2 per share and a 1:1 bonus share issue, subject to shareholder approval.

Financial highlights

• FY2025 total income increased 19.1% year-over-year to INR 3,482 million; EBITDA margin at 36.2%; PAT margin at 19.2%.

• Q4 FY25 total income was INR 961 million, up 31.4% year-over-year; EBITDA margin at 36.1%; PAT margin at 19.1%.

• FY25 net profit reached INR 668 million, up 36.8% year-over-year; basic EPS for FY25 was Rs 30.0 (up 36.2% YoY).

• FY25 PBT grew 42.4% year-over-year to Rs 890 million.

• Cash flow from operations for FY25 was Rs 946.13 million, up from Rs 608.92 million in FY24.

Outlook and guidance

• Targeting a quarterly revenue run rate of INR 1.25 billion by the end of FY2026 and revenues exceeding Rs 5,000 million by FY26.

• CapEx guidance for FY2026 is INR 900 million, excluding INR 400–500 million planned for biologics over two years.

• Margins expected to remain stable, with possible fluctuation of ±2%.

• Focus on operational excellence, risk management, and customer partnerships to sustain growth.